A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

British Journal of Haematology

Volumn 160, Issue 5, 2013, Pages 714-717

  Popat, Rakesh ^a,b   Plesner, Torben ^c   Davies, Faith ^d   Cook, Gordon ^e   Cook, Mark ^f   Elliott, Peter ^g   Jacobson, Eric ^g   Gumbleton, Todd ^a   Oakervee, Heather ^a   Cavenagh, Jamie ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LILLEBAELT HOSPITAL   (Denmark)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g GLAXOSMITHKLINE   (United States)

Author keywords

Clinical trials; Myeloma; Renal medicine

Indexed keywords

BORTEZOMIB; CLODRONIC ACID; CREATININE; CYCLOPHOSPHAMIDE; LENALIDOMIDE; MELPHALAN; RESVERATROL; THALIDOMIDE;

ANEMIA; AUTOGRAFT; CANCER GROWTH; CANCER RECURRENCE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEMODIALYSIS; HUMAN; INFECTION; KIDNEY FAILURE; LETTER; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CREATININE; DEHYDRATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; STILBENES; TREATMENT FAILURE; VOMITING;

EID: 84873996774     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12154     Document Type: Letter

References (9)

1. Baur, J.A. & Sinclair, D.A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery, 5, 493-506.
2. Bhardwaj, A., Sethi, G., Vadhan-Raj, S., Bueso-Ramos, C., Takada, Y., Gaur, U., Nair, A.S., Shishodia, S. & Aggarwal, B.B. (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-κB regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 109, 2293-2302.
3. Bird, J.M., Owen, R.G., D'Sa, S., Snowden, J.A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgan, G., Cavenagh, J., Low, E. & Behrens, J. (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 154, 32-75.
4. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
5. Howells, L.M., Berry, D.P., Elliott, P.J., Jacobson, E.W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W.P. & Gescher, A.J. (2011) Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prevention Research (Philadelphia, Pa.), 4, 1419-1425.
6. Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, N.R., Kinghorn, A.D., Mehta, R.G., Moon, R.C. & Pezzuto, J.M. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-220.
7. Jazirehi, A.R. & Bonavida, B. (2004) Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics, 3, 71-84.
8. Michishita, E., Park, J.Y., Burneskis, J.M., Barrett, J.C. & Horikawa, I. (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Molecular Biology of the Cell, 16, 4623-4635.
9. Sirtris Pharmaceuticals, Inc. (2009) SRT501 Investigator's Brochure Oncology. Sirtris Pharmaceuticals, Inc., Cambridge, MA, USA.